このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Esperion Therapeutics 将来の成長

Future 基準チェック /56

Esperion Therapeuticsは、59.3%と31.4%でそれぞれ年率59.3%で利益と収益が成長すると予測される一方、EPSはgrowで61.9%年率。

主要情報

59.3%

収益成長率

61.9%

EPS成長率

Pharmaceuticals 収益成長	27.3%
収益成長率	31.3%
将来の株主資本利益率	n/a
アナリストカバレッジ	Good
最終更新日	28 Jun 2024

今後の成長に関する最新情報

Recent updates

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

May 20

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Feb 28

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Jan 22

Esperion Is Sitting On A Potential Blockbuster Drug

Jan 14

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Jun 19

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Mar 09

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Feb 23

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Aug 26

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Aug 09

Esperion Therapeutics Q2 2022 Earnings Preview

Aug 01

Esperion Therapeutics: 2021 Labors Paying Off In 2022

May 07

Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout

Feb 24

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Analysts Are Reducing Their Forecasts For This Year

May 09

Esperion Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 04

業績と収益の成長予測

NasdaqGM:ESPR - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	639	232	N/A	N/A	3
12/31/2025	412	47	173	112	6
12/31/2024	330	2	124	63	8
3/31/2024	230	-87	-27	-27	N/A
12/31/2023	116	-209	-135	-135	N/A
9/30/2023	103	-208	-141	-141	N/A
6/30/2023	88	-222	-164	-164	N/A
3/31/2023	81	-239	-190	-190	N/A
12/31/2022	75	-234	-175	-175	N/A
9/30/2022	72	-243	-190	-190	N/A
6/30/2022	67	-258	-216	-216	N/A
3/31/2022	89	-235	-214	-214	N/A
12/31/2021	78	-269	-264	-264	N/A
9/30/2021	73	-308	-287	-275	N/A
6/30/2021	62	-325	-305	-292	N/A
3/31/2021	234	-156	-118	-105	N/A
12/31/2020	228	-144	-99	-85	N/A
9/30/2020	219	-101	-67	-67	N/A
6/30/2020	216	-84	-39	-38	N/A
3/31/2020	5	-263	-232	-231	N/A
12/31/2019	148	-97	-71	-70	N/A
9/30/2019	147	-95	-50	-49	N/A
6/30/2019	146	-77	-29	-29	N/A
3/31/2019	145	-68	-14	-14	N/A
12/31/2018	N/A	-202	-149	-149	N/A
9/30/2018	N/A	-180	-155	-155	N/A
6/30/2018	N/A	-175	-153	-153	N/A
3/31/2018	N/A	-173	-140	-140	N/A
12/31/2017	N/A	-167	N/A	-131	N/A
9/30/2017	N/A	-158	N/A	-113	N/A
6/30/2017	N/A	-130	N/A	-91	N/A
3/31/2017	N/A	-101	N/A	-72	N/A
12/31/2016	N/A	-75	N/A	-48	N/A
9/30/2016	N/A	-59	N/A	-40	N/A
6/30/2016	N/A	-55	N/A	-37	N/A
3/31/2016	N/A	-53	N/A	-39	N/A
12/31/2015	N/A	-50	N/A	-38	N/A
9/30/2015	N/A	-46	N/A	-38	N/A
6/30/2015	N/A	-43	N/A	-35	N/A
3/31/2015	N/A	-40	N/A	-32	N/A
12/31/2014	N/A	-36	N/A	-32	N/A
9/30/2014	N/A	-37	N/A	-31	N/A
6/30/2014	N/A	-32	N/A	-27	N/A
3/31/2014	N/A	-30	N/A	-25	N/A
12/31/2013	N/A	-26	N/A	-18	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ESPRは今後 3 年間で収益性が向上すると予測されており、これは貯蓄率 ( 2.4% ) よりも高い成長率であると考えられます。

収益対市場: ESPR今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。

高成長収益: ESPR今後 3 年以内に収益を上げることが予想されます。

収益対市場: ESPRの収益 ( 31.4% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: ESPRの収益 ( 31.4% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ESPRの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Esperion Therapeutics 将来の成長

Future 基準チェック /56

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$0.37 loss

Consensus revenue estimates fall by 12%

Price target decreased by 13% to US$7.41

Forecast breakeven date pushed back to 2025

Price target decreased by 18% to US$9.14

No longer forecast to breakeven

Recent updates

Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.79 loss in 1Q 2023)

Esperion Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Consensus EPS estimates upgraded to US$0.37 loss

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Consensus revenue estimates fall by 12%

Price target decreased by 13% to US$7.41

A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

Esperion Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations

Esperion Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $85.05 million.

Esperion Is Sitting On A Potential Blockbuster Drug

Forecast breakeven date pushed back to 2025

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet

New major risk - Shareholder dilution

Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023

Price target decreased by 18% to US$9.14

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Esperion Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

Consensus EPS estimates upgraded to US$1.99 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Esperion Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. Announces the Results from its Pre-Specified, Primary Prevention Clear Outcomes Subgroup Analysis

Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Forecast breakeven date moved forward to 2024

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment At Endo 2023

Esperion Announces Submission of Supplemental New Drug Applications to U.S. Fda for Nexletol(R) (Bempedoic Acid) Tablet and Nexlizet(R) (Bempedoic Acid and Ezetimibe) Tablet

Price target decreased by 10% to US$10.08

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased by 12% to US$12.22

Price target decreased by 11% to US$10.41

Consensus revenue estimates fall by 24%

Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts

Consensus revenue estimates increase by 22%

Consensus revenue estimates fall by 20%

Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Esperion Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Forecast to breakeven in 2024

Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Esperion Therapeutics, Inc. Announces CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology

Esperion Therapeutics, Inc. Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$12.10

Esperion Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Esperion Announces Bempedoic Acid NEXLETOL Recommends as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol

Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Esperion Therapeutics Q2 2022 Earnings Preview

Esperion Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

High number of new directors

Esperion Therapeutics: 2021 Labors Paying Off In 2022

Price target increased to US$11.67

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

High number of new directors

Esperion Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022